Sareum Holdings sees full-year profit ahead of market expectations

Sareum Holdings said on Tuesday that it expects full-year profit and cash at bank to be ahead of market expectations.

The AIM-listed specialist cancer drug discovery and development business will provide an update on progress with its cancer and autoimmune disease research and development programmes in mid-late October 2017, which is when it expects to report its full year results.

At 1000 BST, the shares were up 10.5% to 0.83p.